The Centers for Disease Control and Prevention (CDC), in collaboration with state and local health departments, is investigating reports of serious adverse events, including deaths, following receipt of injectable ceftriaxone. To date, events have not been associated with a single product manufacturer or lot, and a definitive causal link to ceftriaxone has not been established. CDC is requesting reports of serious adverse events following the administration of ceftriaxone to assist with the ongoing investigation.
Please report to CDC adverse events that meet the following criteria, occurring after September 1, 2024:
- Occurred within 6 hours after receipt of injectable* ceftriaxone in a non-ICU setting, and
- Resulted in death or required cardiopulmonary resuscitation**, and
- Not attributed by the treating provider(s) to a cause other than ceftriaxone administration***
*including both intramuscular and intravenous routes of administration
**cardiopulmonary resuscitation defined as the use of chest compressions and mechanical ventilation or provision of rescue breaths to maintain circulatory flow and oxygenation during cardiac arrest
***such as known infection, other underlying medical condition, or exposure to a medication or medical product other than ceftriaxone
Please make reports to HCA's Communicable Disease Control Division at 714-834-8180. Healthcare providers should report serious adverse events that might be associated with a medical product to FDA’s MedWatch Program and to the product manufacturer.
